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Novelty: This is the first study demonstrating mechanisms by which naive rUCMSC cytotherapy 
completely regress orthotopic mammary carcinoma grafts. The rUCMSC stimulated infiltration 
of CD8+ and CD4+ T cells and NK cells and decreased CD68+ monocytes/macrophages and 
Foxp3+ regulatory T cells in tumor tissues. Microarray analysis and Boyden chamber migration 
assays identified that MCP-1 is crucial for this lymphocyte infiltration. UCMSC-based 
cytotherapy can be a new therapeutic modality for the treatment of mammary carcinoma. 
 
2 
 
 
* Correspondence to: 
Masaaki Tamura, Associate Professor 
Department of Anatomy & Physiology,  
Kansas State University, College of Veterinary Medicine 
Manhattan, KS 66506 
Phone: (785) 532-4825, Fax: (785) 532-4557 
Email: mtamura@vet.ksu.edu
3 
 
Abstract 
Background- Un-engineered human and rat umbilical cord matrix stem cells (rUCMSC) 
attenuate growth of several types of tumors in mice and rats. However, the mechanism by which 
UCMSC attenuate tumor growth has not been studied rigorously.  
Methods-  The possible mechanisms of tumor growth attenuation by rUCMSC were studied 
using orthotopic Mat B III rat mammary tumor grafts in female F344 rats. Tumor-infiltrating 
leukocytes were identified and quantified by immunohistochemical image analysis. Potential 
cytokines involved in lymphocyte infiltration in the tumors were determined by microarray and 
Western blot analysis. The Boyden chamber migration assay was performed for the functional 
analysis of identified cytokines.  
Results-  rUCMSC markedly attenuated the tumor growth; this attenuation was accompanied by 
considerable lymphocyte infiltration. Immunohistochemical analysis revealed that the majority 
of infiltrating lymphocytes in the rUCMSC-treated tumors were CD3+ T cells.  In addition, 
treatment with rUCMSC significantly increased infiltration of CD 8+ and CD4+ T cells and NK 
cells throughout tumor tissue. CD68+ monocytes/macrophages and FoxP3+ regulatory T cells 
were scarcely observed, only in the tumors of the PBS control group.  Microarray analysis of 
rUCMSC identified that monocyte chemotactic protein (MCP)-1 is involved in rUCMSC-
induced lymphocyte infiltration in the tumor tissues.   
Discussion-These results suggest that naïve rUCMSC attenuated mammary tumor growth at least 
in part by enhancing host anti-tumor immune responses. Thus, naïve UCMSC can be used as 
powerful therapeutic cells for breast cancer treatment, and MCP-1 may be a key molecule to 
enhance the effect of UCMSC at the tumor site. 
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We have isolated a cell line from the Wharton’s jelly of rat umbilical cord, termed rat 
umbilical cord matrix stem cells (rUCMSC) (1). Characteristics of this rUCMSC are similar to 
those isolated from human umbilical cord matrix and bone marrow (2, 3) . Both human and 
rUCMSC exhibit tumor tropism (4-6) . Human UCMSC have proven to be useful as gene 
delivery vehicles for targeted gene therapy (4, 6). We previously discovered that intratumoral 
(i.t.) or intravenous (i.v.) injection of naïve rUCMSC is capable of causing complete regression 
of rat mammary tumors in immunocompetent rats (1). Recent studies also indicated that naïve 
human UCMSC alone possess a strong tumoricidal activity against human breast carcinoma cells 
in immunodeficient mice (5, 7). Both human and rUCMSC have been shown to induce apoptosis 
and cell cycle arrest in co-cultured tumor cells by UCMSC-produced tumor cell growth 
regulators (1, 5, 7). Genome-wide microarray analysis revealed that these growth regulators are 
potentially associated with multiple tumor suppressor gene products (8) and cell motility-
associated genes (7).These results suggest that naïve UCMSC can be used for cytotherapy for 
mammary tumors. However, the mechanism by which UCMSC control tumor growth in 
immunocompetent animals is yet to be completely understood. 
The tumor microenvironment, composed of various cell types such as endothelial cells, 
tumor-infiltrating leukocytes (TILs), fibroblasts and extracellular matrix (ECM), is important in 
regulating tumor growth (9-13). Fleming et al. (13) have shown that breast ECM has an ability to 
increase the aggressiveness and tumorigenicity of breast cancer cells. However, a suppressive 
role for stromal cells in the tumor microenvironment is also reported (14-17). Among 
components in the tumor microenvironment, TILs play an important role in tumor attenuation 
(18,19). Particularly, two subsets of lymphocytes, CD8+ T cells and natural killer (NK) cells, are 
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suggested to be involved in tumor attenuation by directly damaging tumor cells (19, 20 ). This is 
supported by the reports that TILs can provide a survival advantage to various cancer patients 
(20-24). In contrast, regulatory T (Treg) cells, a subpopulation of  T cells that have the ability to 
suppress both CD4+ and CD8+ T cell functions (25) indirectly support tumor growth by 
suppressing tumor-specific CD8+ T cells (26). 
Although both naïve human and rUCMSC exhibited strong tumoricidal activity against 
breast carcinoma cells, a bolus treatment with rUCMSC caused complete tumor regression in 
immunocompetent rats (1), whereas human UCMSC did not show such powerful tumor growth 
attenuation effects in an animal study in immunodeficient mice; human UCMSC treatment 
reduced tumor burden by 50% (5). These studies prompted us to speculate an involvement of 
tumor immune response in rUCMSC-dependent strong tumoricidal activity, since 
immunocompetent animals were used only for the rUCMSC study. In support of this speculation, 
lymphocyte infiltration in tumor tissues has been shown to be well-correlated with good clinical 
outcomes in human patients receiving tumor antigen-activated CD8+ T cell infusions for 
metastatic melanoma (27).  
In the present study, we attempted to clarify the mechanisms by which naïve rUCMSC 
attenuate/regress tumor growth in vivo and in vitro. Here we report for the first time that 
treatment with rUCMSC significantly increases lymphocyte infiltration in the tumor tissues, and 
that TILs, primarily CD8+ T cells and NK cells, induce tumor cell death, thereby regressing 
tumors. The primary mechanism by which rUCMSC caused significant lymphocyte infiltration 
in the tumor tissues appears to be due to the increased monocyte chemotactic protein (MCP)-1 
secretion from rUCMSC that had homed tumor tissues.  
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Materials and Methods 
Cell culture 
rUCMSC were harvested from E19 pregnant rats. The method to isolate and culture rUCMSC 
was previously described (1). rUCMSC were maintained in low-serum (defined) medium, 
containing the following mixture per 100 mL: 57 mL low-glucose DMEM (Invitrogen, Carlsbad, 
CA), 37 mL MCBD 201 (Sigma-Aldrich, St. Louis, MO), 2 mL fetal bovine serum (FBS; 
Atlanta Biologicals, Inc., Lawrenceville, GA), 1 mL of 100x insulin-transferrin-selenium-X 
(Invitrogen); 1 mL of 0.15 g/mL AlbuMax I (Invitrogen), 1 mL of 100 x Pen/Strep (Invitrogen), 
10 nmol/L dexamethasone (Sigma), 100 µmol/L ascorbic acid 2-phosphate (Sigma), 10 ng/mL 
epidermal growth factor (R&D Systems, Minneapolis, MN), and 10 ng/mL platelet derived 
growth factor-BB (R&D Systems). Cells were maintained at 37Ԩ in a humidified atmosphere 
containing 5% CO2. The rat mammary adenocarcinoma cell line, Mat B III (American Type 
Culture Collection, Manassas, VA), was maintained in McCoy’s 5A modified medium 
(Invitrogen) supplemented with 10% FBS, 100 units/mL penicillin, and 100 µg/mL streptomycin 
(Invitrogen). Cells were cultured at 37Ԩ in a humidified atmosphere containing 5% CO2. 
 
In vivo studies 
All experiments were carried out using protocols approved by the Institutional Animal Care and 
Use Committee of Kansas State University (#2681). Female 4 to 5 month-old F344 rats were 
obtained from Charles River Laboratories (Wilmington, MA). All rats were housed in a clean 
facility and held for 1 week to acclimatize. On day 0, 1 x 105 Mat B III cells suspended in 100 
µL of PBS were implanted orthotopically into the abdominal mammary fat pad under isoflurane 
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anesthesia. All rats were randomized into two treatment groups: 1) i.t. PBS injection (n = 5); 2) 
i.t. rUCMSC (1 x 106) transplant (n = 9). On day 4 post–tumor cell transplantation, rUCMSC (1 
x 106) suspended in 100 µL of PBS were injected i.t. Tumor bearing rats given i.t. 100 µL of 
PBS on day 4 served as control rats. Tumors became palpable starting from day 7; tumors were 
measured every 3 to 4 days with calipers under isoflurane anesthesia. A portion of rUCMSC 
treated rats (5 rats) and PBS treated rats were sacrificed 14 days after tumor cell inoculation. 
Tumor tissues were removed, fixed in 10% buffered neutral formalin, and used for histological 
and immunohistochemical analysis. Fresh-frozen tissue was also prepared using O.C.T. 
Compound (Sakura Finetek USA, Torrance, CA). The remaining 4 rUCMSC-treated rats were 
used for the monitoring of the tumor size until the tumor size was insignificant. 
 
Microarray analysis 
To examine chemoattractant gene expression, a microarray study was conducted comparing 
naïve rUCMSC and rUCMSC co-cultured with Mat B III cells. rUCMSC and Mat B III cells 
were co-cultured using 10 cm Transwell culture dishes in which the insert membrane pore size is 
0.4 µm (Corning, Lowell, MA). rUCMSC (1 x 105) were seeded in the bottom culture plate and 
Mat B III cells (1.5 x 106) were added to the insert on the following day. After 48 hours co-
culture, total RNAs were isolated using TRIzol Reagent (Invitrogen) following the 
manufacturer’s instructions. Quality and quantity of total RNA samples were assessed using an 
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). The microarray analysis, 
including quality control, was conducted by the Gene Expression and Genomics Unit at the 
National Institute on Aging (NIA) using RatRef-12 BeadChip (Illumina, San Diego, CA). For 
each sample, biotinylated cRNAs were prepared using an Illumina total prep RNA amplification 
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kit (Applied Biosystems, Foster City, CA, USA). Overall microarray analysis was carried out 
according to the method described previously (28). Statistical analysis was processed using a Z 
score developed at NIA (29). Z scores were calculated by subtracting the average gene intensity 
from the raw intensity data for each gene and dividing that result by the S.D. of all the measured 
intensities. Gene expression differences between any two experiments were calculated by taking 
the difference between the observed gene Z scores. Genes relevant to cell migration, such as 
chemokines and cytokines, which showed 1.5 times higher expression than in the control group, 
were selected for the final gene list. 
 
Cell migration assay 
Migration of peripheral blood mononuclear cells (PBMC) was carried out using Transwell cell 
culture plates with 5 µm pores (Corning) according to the previously described method (30). The 
bottom membrane of the Transwell inserts was coated with Matrigel (200 µg/ml) before use. In 
the bottom of the Transwell culture plate, 3 x 104 rUCMSC or Mat B III cells were seeded and 
cultured for 24 hrs. PBMC (0.5 x 105) isolated from the peripheral blood obtained from an adult 
female F344 rat were suspended in 100 µl of defined medium and added to the Transwell insert. 
Antibodies against MCP-1(Santa Cruz Biotechnology, Santa Cruz, CA) or control IgG were 
added in the lower chamber at the concentration of 2 or 4 µg/well 3 hrs prior to the addition of 
PBMC. Cells were incubated at 37Ԩ for 3 hrs. At the end of the incubation, the membrane of the 
Transwell insert was fixed in methanol, stained with Giemsa solution for 15 min, and dried 
overnight. The membrane was removed from the insert and embedded in Permount (Fisher 
Scientific, Pittsburgh, PA). The number of the PBMCs stained with Giemsa solution on the 
underside of the membrane (i.e., is the side facing the rUCMSC or Mat B III cells in the bottom 
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chamber) was counted under the microscope.   
 
The comparison of the expression of MCP-1 in rUCMSC and Mat B III by Western blot 
analysis 
Western blot analysis was conducted to examine chemoattractant protein expression. rUCMSC 
and Mat B III cells were co-cultured using 6-well Transwell culture plates in which the insert 
membrane pore size is 0.4 µm (Corning). rUCMSC (5 x103) were seeded in the bottom culture 
plate and Mat B III cells (7.5 x 104) were added to the insert on the following day. After 72 hours 
co-culture, total cellular protein of rUCMSC or Mat B III was prepared using RIPA buffer 
(Sigma). Protein samples were separated by 12% SDS-PAGE, electroblotted onto nitrocellulose 
membrane (GE Healthcare, Uppsala, Sweden) and blocked with 4% nonfat dry milk in 0.1% 
Tween 20 in phosphate buffered saline (PBST) for 1 hr at room temperature. The membranes 
were washed and incubated with antibody against MCP-1 (1:200, Santa Cruz Biotechnology) 
with 4% nonfat dry milk in PBST for 1 hr at room temperature, followed by incubation with a 
horseradish peroxidase-conjugated anti-rabbit IgG secondary antibody (1: 2000, GE Healthcare) 
for 1 hr at room temperature. The protein expression signal was detected with SuperSignal West 
Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL). GAPDH was used as the loading 
control of sample by reprobing with an anti-GAPDH antibody (1:2000, Santa Cruz 
Biotechnology). 
 
Histological analysis 
Paraffin-embedded mammary tumor tissues were sectioned at 4 µm and stained with 
hematoxylin and eosin for histological examination. Some unstained sections were selected for 
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immunohistochemistry to determine the CD antigens on the lymphocytes in the tumor tissues. 
Slides were deparaffinized and rehydrated before staining. The heat-induced antigen unmasking 
was performed in citrate buffer for 5 minutes using an autoclave. Sections were then incubated 
with 3 % hydrogen peroxide in methanol for 3 minutes to block endogenous peroxide activity. 
For CD4 and Foxp3 immunostaining, fresh-frozen tissue sections (4 µm) fixed by acetone were 
prepared and incubated in 4% non-fat skim milk in PBS at room temperature for 20 minutes. The 
dilution of antibodies for CD3 (Dako North America, Carpinteria, CA), CD8 (BD Biosciences, 
Rockville, MD), CD20 (Santa Cruz Biotechnology) and CD68 (Santa Cruz Biotechnology) was 
1:50. The dilution of antibodies for CD4 (AbD Serotec, Raleigh, NC), Foxp3 (Aviva System 
Biology, San Diego, CA) and NK cell marker (Santa Cruz Biotechnology) was 1:100. Sections 
were incubated with the primary antibodies for 60 minutes at room temperature. For 
immunostaining for CD4 and CD20, sections were incubated with biotin-conjugated antibody 
against mouse IgG and goat IgG (Vector Laboratories, Burlingame, CA), respectively, followed 
by reaction with the avidin-biotin peroxidase complex (ABC) reagent (Vector Laboratories) for 
40 minutes at room temperature. For immunostaining for CD3, CD8 and CD68, Foxp3 and NK 
cell marker, sections were incubated with biotin-conjugated antibody against rabbit IgG (Vector 
Laboratories) before reaction with the ABC reagent (Vector Laboratories). Peroxidase activity 
was visualized with 3, 3’-diaminobenzodine tetrahydrochloride (Sigma). Sections were lightly 
counterstained with Mayer’s hematoxylin. The average number of each cell types (bar graphs) 
was determined by analyzing ten tumor areas in each treatment group and was expressed as cell 
number per high power (400x) field. 
 
Statistical analysis 
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All data are reported as mean ± SE. Data were analyzed by Student t test. Group comparisons 
were deemed significant for 2-tailed P values below 0.05. 
 
Results 
 rUCMSC treatment significantly attenuates the growth of mammary tumor grafts in vivo  
I.t. injection of rUCMSC significantly attenuated the growth of orthotopic grafts of rat mammary 
tumors as compared with those of PBS-injected control rats (sham, Fig. 1A). The tumor growth 
reached a peak at the 16-19 days after tumor inoculation and regressed thereafter. Tumor size 
was insignificant 40 days after tumor cell inoculation. In PBS-injected control rats, the tumors 
grew continuously; rats were sacrificed 14 days after tumor inoculation. To evaluate leukocyte 
infiltration in the tumor tissues, a portion of rats were sacrificed at 14 days after tumor cell 
inoculation and tumor tissues were removed for immunohistochemical analysis. The tumor 
weights measured on day 14 showed a significant difference between rUCMSC- and PBS-
injected groups (Fig. 1B).  
 
rUCMSC treatment stimulated infiltration of numerous lymphocytes into the tumor 
As shown in Fig. 2A, PBS-treated orthotopic tumors in the mammary fat pad were composed of 
solidly packed round to oval cells. All tumor cells had irregularly-shaped and-sized nuclei with 
prominent nucleoli. A large number of mitotic figures were also commonly observed. rUCMSC 
treatment significantly increased the amount of ECM deposition and decreased the number of 
tumor cells within the tumor tissues (Fig. 2B). In addition, rUCMSC treatment caused infiltration 
of numerous lymphocytes, but only a small number of neutrophils, in the peritumoral area of the 
tumor mass. This leukocyte infiltration was not observed in the PBS control group (Fig. 2A).   
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rUCMSC treatment increased the infiltration of CD4+ and CD8+ T cells and NK cells and 
decreased macrophages and Treg cells in the tumor 
To identify TILs populations, immunohistochemical analysis was performed using antibodies 
against CD3 (T cells), CD20 (B cells), CD4 (helper T cells), CD8 (cytotoxic T cells), Foxp3 
(Treg) and CD68 (monocytes/macrophages). As shown in Fig. 3, rUCMSC treatment caused a 3 
fold increase of CD3+ cells (average 150 cells/field) over the PBS-treated control (average 50 
cells/field). Treatment with rUCMSC also caused a 3 fold increase of CD20+ cells (average 30 
cells/field) over the control tumors. However, CD20+ cells constituted only 20 % of total 
lymphocytes infiltrating the tumor tissue after the treatment, indicating that the main component 
of lymphocytes in the tumor tissue was T cells rather than B cells (Fig. 3). In the subpopulation 
of T cells, treatment with rUCMSC significantly increased the number of both CD4+ (3 fold) and 
CD8+ cells (2 fold, Fig. 3). The average number of CD8+ cells was higher than that of CD4+ 
cells. On the contrary, a small number of Foxp3+ cells were observed only in the PBS group, but 
not in the rUCMSC treated group (Fig. 3). Although NK cells were not a major component of 
theTILs, NK cells were also significantly higher (1.8 fold higher) in the rUCMSC treated group 
than in the control group. Interestingly, CD68+ cells were infrequently observed only in the PBS 
group, but not in the tumors treated with rUCMSC (Fig. 3). These results indicate that rUCMSC 
treatment caused the tumor tissue infiltration of helper and cytotoxic T cells and NK cells, but 
decreased Treg cells and monocytes/macrophages. 
 
Microarray analysis of cytokines related for cell migration 
Gene expression of rUCMSC co-cultured with Mat B III was compared with naïve rUCMSC. A 
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partial list of the highly up- or down-regulated chemokines, cytokines and immune cell 
migration-related genes which showed more than 1.5 times difference in Z-ratio is presented in 
Table 2. Notably, expression of MCP-1 was significantly increased in rUCMSC (13.88 fold) 
when they were co-cultured with Mat B III cells. Since MCP-1 is a one of the chemoattractants 
associated with lymphocyte infiltration, MCP-1 is a potential candidate for stimulating 
lymphocyte migration into the rUCMSC-treated tumors.  
 
MCP-1 expression is increased in rUCMSC when they were co-cultured with Mat B III 
cells 
To confirm the above mRNA expression results from microarray analysis in protein levels, the 
expression of MCP-1 was semi-quantified by Western blot analysis. As shown in Fig. 4, the basal 
expression of MCP-1 in rUCMSC was significantly larger than that in Mat B III. Furthermore, 
the expression of the MCP-1 in rUCMSC was significantly increased when they were co-
cultured with Mat B III cells. These results suggest that MCP-1 expression is sensitively 
upregulated in response to the presence of Mat B III mammary carcinoma cells.  
 
rUCMSC stimulated PBMC migration by MCP-1 secretion 
To examine whether PBMC migrate toward rUCMSC and whether this migration is controlled 
by MCP-1, PBMC migration was examined by the Boyden chamber assay using Transwell 
culture system in the presence or absence of MCP-1 neutralizing antibody. As shown in Fig. 5, 
rUCMSC increased approximately two -fold the infiltration of PBMC into the Matrigel coated 
membrane of the Transwell insert. The number of migrating PBMC was significantly decreased 
by adding 4µg/well of neutralizing antibody against MCP-1, indicating that the secretion of 
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MCP-1 from rUCMSC is an important factor for migration of PBMC, which are mainly 
lymphocytes. In the control study, the treatment of Mat B III with neutralizing antibody against 
MCP-1 did not show much effect on the PBMC infiltration to the bottom of the Transwell 
membrane. This result suggests that PBMC migration toward rUCMSC is specific. In the control 
experiment with anti-GFP antibody instead of MCP-1 antibody, the number of the membrane-
infiltrating PBMC was slightly higher than that without any antibody, but no statistically 
significant difference was observed. These results suggest that the effect of the  
MCP-1 antibody is specific and PBMC specifically migrate toward rUCMSC by sensing the 
MCP-1gradient.  
 
Discussion 
It has been shown that stem cells are useful therapeutic tools for various diseases 
including cancers. UCMSC are unique MSC (2, 3) and are considered to be safe therapeutic 
cells, since systemic or subcutaneous administration of UCMSC does not result in adverse 
effects or tumor formation in the recipients (4, 31). In preclinical animal studies involving the 
use of naïve UCMSC for cancer treatment, rUCMSC have demonstrated a remarkable ability to 
cause complete regression of Mat B III rat mammary tumors in vivo (1). In addition, un-
engineered human UCMSC have been shown to attenuate human breast cancer xenografts in a 
SCID mouse model (5). However, the mechanism by which naïve UCMSC attenuate tumor 
growth has yet to be fully understood. Although previous studies have demonstrated that 
diffusible factors produced by naïve UCMSC play important roles in attenuation of the growth 
of tumor cells in vitro, the nature of factors and the mechanisms of in vivo tumor growth 
attenuation are yet to be clarified. Therefore, the present study was focused on clarifying the 
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mechanism by which rUCMSC attenuate the growth of mammary tumors both in vitro and in an 
in vivo rat model. The present study shows that rUCMSC enhance host anti-tumor immune 
responses by recruiting primarily CD4+ and CD8+ T cells and NK cells to tumor tissues, thus 
significantly attenuating mammary tumor growth. The results further suggest that a potential 
mechanism by which naïve rUCMSC increase lymphocyte infiltration into the tumor tissues is 
due to the increase of MCP-1 secretion.  
The present study showed that treatment with naive rUCMSC significantly attenuated 
the growth of orthotopic rat mammary tumors (Fig. 1). This is consistent with the previous 
reports (1), in which a single treatment with rUCMSC completely abolished rat mammary 
tumors. Immunohistochemical analysis of tumor tissues treated with rUCMSC revealed a 
significant increase of lymphocyte infiltration in the tumor tissues (Fig. 2). Detailed analysis 
further revealed that the major component of infiltrating lymphocytes in rUCMSC-treated tumor 
tissues is CD8+ cells (approximately 52% of total lymphocytes are CD8+ T cells and 37.5 % 
cells correspond to CD4+ T cells, Fig. 3). Although CD20+ cells were also increased in the 
rUCMSC treated tumors, CD20+ cells comprised less than 12% of total lymphocytes (Fig. 3). In 
addition, a unique discovery in the present study was that no CD68+ or Foxp3+ cells were 
detected in tumor tissues in rUCMSC-treated mice (Fig. 3E), although a small number of CD68+ 
and Foxp3+ cells were consistently detected in untreated tumors. These results strongly suggest 
that treatment with naïve rUCMSC significantly enhanced host tumor immune responses by 
increasing CD8+ cytotoxic T cells and decreasing CD68+ macrophages and Foxp3+ Treg cells. 
In a variety of human cancers, it has been shown that TILs, such as cytotoxic T cells (CD8+), 
helper T cells (CD4+), and Treg cells (Foxp3+) play important roles in controlling tumor growth 
(26). Among those TILs CD8+ T cells are the major subset of T cells, and they can become 
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tumor-specific cytotoxic cells by direct recognition of tumor antigens presented on the tumor 
cells (24). Infiltration of CD8+ T cells in the tumor site is shown to be associated with a good 
prognosis in malignant tumors such as colorectal, ovarian and esophageal carcinoma (20-23). 
These reports support the idea that rUCMSC-dependent tumor growth attenuation is associated 
with stimulation of host anti-tumor immune responses via CD8+ T cell infiltration in the tumor 
tissues. Furthermore, an increase of CD4+ helper T cells in rUCMSC-treated tumors (Fig. 3) 
further supports the idea of stimulation of host anti-tumor immune responses, since helper T cells 
assist in activation and proliferation of cytotoxic T cells (32). Decrease of Treg cells also 
supports an increase of cytotoxic T cells, since they directly attenuate T cell proliferation (33). 
Indeed, therapies to decrease the Treg cell population or to blunt the function of Treg cells are 
effective in attenuating various tumors (34). In contrast, numerous reports indicate an increase of 
Treg cells in tumor tissues correlates with tumor progression and poor prognosis of multiple 
organ type cancers including breast cancer (35). 
In the present study, rUCMSC treatment also increased NK cells in tumor tissues (Fig. 
3). Since NK cells are an important component of anti-tumor immune reactions in addition to 
cytotoxic T cells, an increase of NK cells enhances anti-tumor immune reactions. Although NK 
cells are innate immune cells and do not have the specificity to particular tumors, they quickly 
induce apoptosis in tumor cells thereby attenuating tumor burden (36). Taken together, these 
results clearly indicate that treatment with rUCMSC increases the infiltration of the CD8+ T cells 
and NK cells into tumor tissues and decreases CD68+ macrophages and Foxp3+ Treg cells, 
thereby reducing the tumor volume. The granzyme-positive population in the CD8+ T cells in 
the tumor tissues should be clarified in future studies.  
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Our results from the present study indicate that rat PBMC migration is directed toward 
rUCMSC rather than Mat B III mammary carcinoma cells (Fig. 5). This migration is associated 
with MCP-1, as MCP-1 neutralizing antibody attenuates PBMC migration to the rUCMSC (Fig. 
5). This is directly relevant to the histological findings showing that i.t. injection of rUCMSC 
induced infiltration of numerous lymphocytes into the tumor tissues (Figs. 2 and 3). MCP-1 is 
shown to play an important role in migration of lymphocytes and NK cells to tumor tissues. 
MCP-1 is a member of the chemokine-2 subfamily that attracts and activates monocytes or 
lymphocytes at subnanomolar concentrations (37-39). Expression of MCP-1 in tumor tissues is 
shown to be sufficient for induction of cytotoxic T cell migration to tumor tissues in mouse 
xenograft studies (40). Tsuchiyama et al. (41) have reported that a therapy with recombinant 
adenovirus vector (rAd) expressing suicide gene, HSV thymidine kinase, and MCP-1 completely 
eradicated hepatocellular carcinoma by the recruitment of NK cells. The present study suggests 
that rUCMSC traffic to tumor tissues and recruit T cells to the tumor site through increased 
MCP-1 secretion. To the best of our knowledge, this study is the first report showing that 
rUCMSC secrete a chemoattractant such as MCP-1 and induce lymphocyte infiltration. Hence, 
this report suggests that MCP-1 could be a potential therapeutic target to enhance local immune 
responses to attenuate mammary carcinoma.  
Interestingly, CD68+ cells were not observed in the rUCMSC-treated tumors despite the 
fact that CD68+ macrophages are known to be attracted by MCP-1 (42). The likely explanation 
is that a factor inhibitory to macrophages might be secreted from rUCMSC or Mat B III cells. 
Indeed, the microarray analysis indicated that the expression of macrophage inhibitory factor 
(MIF) was significantly increased (3.4 fold) in rUCMSC co-cultured with Mat B III cells (Table 
1). Therefore, it is likely that increased MIF expression may have stimulated an exodus of 
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macrophages from the rUCMSC-treated tumors, thus assisting rUCMSC-dependent attenuation 
of tumor growth. Clarification of the role of MIF in rUCMSC-treated tumors requires further 
studies.  
Regarding macrophage infiltration in the tumor tissues, clinical studies have sought to 
identify correlations between macrophage density and prognosis. A summary in a review by 
Bingle et al. (43) using a meta-analysis showed that in >80% of the cases, an increased 
macrophage density in tumor tissues was associated with poor prognosis, and the remaining 20% 
of cases were split between having no effect and those with good prognosis. This was confirmed 
with simple histological evaluation of macrophage density, which showed that macrophage 
density in itself was an independent predictor of poor outcome (44, 45). In consideration of these 
reports, the microenvironment without macrophages results in a better probability for attenuating 
tumor growth. However, further experiments are required to clarify the relationship between the 
decrease of macrophage density and the effect of rUCMSC on tumor growth attenuation.  
Among many tissue-originated multipotent stem cells, UCMSC are very usable due to 
unethical abundant resources, the simplicity of their preparation method (46), bankability (47), 
low immunogenicity (48, 49), and tropism to inflammatory tissues such as tumor tissues (1, 4, 6) 
etc. In particular, human UCMSC apparently escape the host immune responses by multiple 
mechanisms (8); they express MHC class I but not class II antigens; they are negative for other 
co-stimulatory antigens such as CD80 and CD86 (50, 51); they produce large amounts of 
tolerogenic interleukin-10 and transforming growth factor-β and express human leukocyte 
antigen G (HLA-G) at higher levels than bone marrow derived mesenchymal stem cells (50-52). 
This poor immunogenicity allows human UCMSC to be usable for allogeneic transplantation in 
potential human applications. In relation to this poor immunogenicity, it is noteworthy to cite 
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that Chao et al. have reported a successful transplantation of human UCMSC-derived islet-like 
cells in diabetic rats without using immunosuppressants (53). The tropism of UCMSC to the 
inflammatory tissues, such as tumor tissues, make this cell also usable as targeted drug or gene 
delivery vehicles. Recent reports have shown that human UCMSC engineered to express 
interferon (IFN)-β, which is a strong apoptosis inducer, shown to be migrated to metastatic 
human breast tumor nodules in the lung (4) or to the bronchioloalveolar carcinoma nodules (6), 
produced sufficient amounts of the IFN-β in the tumor tissues and significantly attenuated tumor 
growth in mice. Therefore, human UCMSC engineered to express MCP-1 are expected to 
migrate to the tumor tissues, recruit a large numbers of CD8+, CD4+ T cells and NK cells to the 
tumor sites, and control tumor growth. To ensure these potential applications, further studies are 
needed to confirm above mentioned possibilities. Although a live cell therapy with multipotent 
stem cells holds a significantly possibilities, a potential limitation of this cell therapy could be a 
migration to unexpected tissues and differentiations. Therefore, safety of live cell therapy and 
fate of multipotent stem cells in human body should be carefully clarified in the future.   
In conclusion, bolus treatment with naive rUCMSC significantly attenuated the growth of 
orthotopic rat mammary carcinoma grafts. This tumor growth attenuation is associated with a 
marked increase of CD8+ and CD4+ T cell and NK cell infiltration and escape of CD68+ 
macrophages and Foxp3+ Treg cells from tumor tissues. Recruitment of T cells and NK cells and 
an escape of CD68+ cells appear to be mediated by MCP-1 and MIF, respectively, and they were 
secreted mainly from the rUCMSC. Thus, the rUCMSC traffic to tumor tissues, recruit cytotoxic 
lymphocytes by the secretion of lymphocyte migration cytokines such as MCP-1 and MIF, 
thereby controlling tumor growth. UCMSC-based cytotherapy may be a new therapeutic 
modality for the treatment of mammary carcinoma. 
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Table 1. Microarray analysis of rUCMSC and those co-cultured with Mat B III mammary tumor 
cell 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Gene description
Z ratio of co-cultured  
rUCMSC/naïve rUCMSC 
Ccl1 
Ccl2 
Ccl7 
Il1rl1 
Cxcl16 
Fst 
Ptrn 
Cxcl12 
Mif 
Ltbp2 
Csf1 
Maf 
Tnfaip8_predicted 
Ifitm3 
Htra1 
Tnfrsf12a 
Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 
Chemokine (C-C motif) ligand 2, Monocyte chemoattractant protein-1 
Chemokine (C-C motif) ligand 7 
Interleukin1 receptor-like 1 
Chemokine (C-X-C motif) ligand 16 
Follistatin 
Protein tyrosine phosphatase, receptor type, N 
Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 
Macrophage migration inhibitory factor 
Latent transforming growth factor beta binding protein 2 
Colony stimulating factor 1 (macrophage) 
Monocyte to macrophage differentiation-associated 
Tumor necrosis factor, alpha-induced protein 8 
Interferon induced transmembrane protein 3 
HtrA serine peptide 1 
Tumor necrosis factor receptor superfamily, member 12a 
16.05
13.88 
11.88 
7.82 
5.55 
4.79 
4.10 
3.70 
3.37 
3.28 
3.14 
2.93 
2.47 
2.16 
1.91 
1.61 
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Figures 
 
Figure 1. Bolus injection of naïve rUCMSC in tumors significantly suppressed growth of  
orthotopic Mat B III autografts in F344 rats. 
 
 
Figure 1. Bolus injection of naïve rUCMSC in tumors completely attenuated the growth of orthotopic 
Mat B III grafts in a syngeneic F344 rat model. A single i.t. administration of rUCMSC (1 million cells, n=9) 
significantly attenuated the Mat B III tumor growth curve (1 million Mat B III cells) and completely 
regressed the tumors at day 40 (panel A). Five each of rUCMSC‐ or PBS‐ treated rats were sacrificed 14 
days after tumor cell inoculation. The average tumor weight in rUCMSC‐treated rats was significantly 
smaller than that in PBS‐treated rats (n=5, panel B). *, P <0.05 compared with PBS‐treated control. 
26 
 
 
 Figure 2. Mononuclear leukocyte infiltration was significantly increased in rUCMSC treated  
orthotopic Mat B III grafts. 
 
 
Figure 2. Mononuclear leukocyte infiltration was significantly increased in rUCMSC‐treated orthotopic 
Mat B III grafts. Samples were prepared as described in Materials and Methods and subjected to 
histological analysis after H&E staining. The pictures represent typical PBS‐ and rUCMSC‐treated tumors. 
As shown in panel A, a majority of cells in the PBS‐treated tumors are tumor cells (inset), whereas panel 
B shows that a large portion in the tumor was composed of connective tissues (areas with pinkish color) 
and a large number of mononuclear cells (inset). Scale bars = 200 m. 
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Figure 3 
 
Figure 3. Detection of specific lymphocyte populations in PBS‐ and rUCMSC‐treated tumors. rUCMSC 
treatment significantly stimulated infiltration of CD3, CD4, CD20,CD8+ and NK cells but attenuated 
Foxp3+ and CD68+ cells in Mat B III mammary tumors. Samples were prepared and subjected to 
immunohistochemical analysis as described in Materials and Methods. The pictures represent typical 
pictures of each antibody staining. The original magnification of pictures of CD3, CD20, CD8, NK marker 
and CD68 is x100 and of CD4 and Foxp3 is x200. The average number of each cell types (bar graphs) was 
determined by analyzing ten tumor areas in each treatment group and were expressed as cell number 
per high power (400x) field. The arrow shows a CD68+ cell. *, P <0.05 compared with PBS‐treated 
control. 
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Figure 4. Expression of MCP‐1 in rat UCMSC and Mat B III cells was detected by Western blot 
analysis. 
 
 
Figure 4. Indirect co‐culture of a small number of rUCMSC and Mat B III significantly increased MCP‐1 
expression in rUCMSC. Three days after co‐culture the whole cell lysate from each cell type was 
separately prepared and subjected to Western blot analysis. Samples were prepared as described in 
Materials and Methods. The average expression levels of MCP‐1 were normalized by GAPDH, and are 
displayed in the histogram. Sample preparation and Western blot analysis were performed three times 
with duplicate determinations. The picture represents typical blotting results. *, P<0.05 compared with 
Mat B III. , P<0.05 compared with rUCMSC without co‐culture. 
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Figure 5. Effect of anti‐mouse MCP‐1 antibodies on the migration of rat PBMC toward either 
rUCMSC or Mat B III carcinoma cells in the Boyden chamber. 
 
 
Figure 5. Addition of anti‐mouse MCP‐1 antibodies significantly attenuated the migration of rat 
 PBMC (peripheral blood mononuclear cells) toward either rUCMSC or Mat B III cells in the Boyden 
chamber assay. Panel A shows the migrated PBMC cells (purple colored cells) on the lower surface of the 
membrane. Antibody against MCP‐1 was added in the lower chambers as noted. Panel B shows the 
summarized results from the migration assay. The experiment was performed twice with triplicate 
determinations. Arrows show the migrated leukocytes. *, P<0.05  
compared with Mat B III. **, P < 0.05 compared with rUCMSC. 
